Financial ties between leaders of influential US professional medical associations and industry: cross sectional study

Abstract Objective To investigate the nature and extent of financial relationships between leaders of influential professional medical associations in the United States and pharmaceutical and device companies. Design Cross sectional study. Setting Professional associations for the 10 costliest disease areas in the US according to the US Agency for Healthcare Research and Quality. Financial data for association leadership, 2017-19, were obtained from the Open Payments database. Population 328 leaders, such as board members, of 10 professional medical associations: American College of Cardiology, Orthopaedic Trauma Association, American Psychiatric Association, Endocrine Society, American College of Rheumatology, American Society of Clinical Oncology, American Thoracic Society, North American Spine Society, Infectious Diseases Society of America, and American College of Physicians. Main outcome measures Proportion of leaders with financial ties to industry in the year of leadership, the four years before and the year after board membership, and the nature and extent of these financial relationships. Results 235 of 328 leaders (72%) had financial ties to industry. Among 293 leaders who were medical doctors or doctors of osteopathy, 235 (80%) had ties. Total payments for 2017-19 leadership were almost $130m (£103m; €119m), with a median amount for each leader of $31 805 (interquartile range $1157 to $254 272). General payments, including those for consultancy and hospitality, were $24.8m and research payments were $104.6m—predominantly payments to academic institutions with association leaders named as principle investigators. Variation was great among the associations: median amounts varied from $212 for the American Psychiatric Association leaders to $518 000 for the American Society of Clinical Oncology. Conclusions Financial relationships between the leaders of influential US professional medical associations and industry are extensive, although with variation among the associations. The quantum of payments raises questions about independence and integrity, adding weight to calls for policy reform.

[1]  B. Thombs,et al.  Pathways to independence: towards producing and using trustworthy evidence , 2019, BMJ.

[2]  D. Morgan,et al.  2019 Update on Medical Overuse: A Review. , 2019, JAMA internal medicine.

[3]  Fabrice Andre,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Godlee,et al.  Commercial interests, transparency, and independence: a call for submissions , 2019, BMJ.

[5]  P. Glasziou,et al.  Reforming disease definitions: a new primary care led, people-centred approach , 2019, BMJ Evidence-Based Medicine.

[6]  Akihiko Ozaki,et al.  Pharmaceutical Company Payments to Executive Board Members of Professional Medical Associations in Japan , 2019, JAMA internal medicine.

[7]  J. Halter,et al.  Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. , 2019, The Journal of clinical endocrinology and metabolism.

[8]  I. Jatoi,et al.  Clinical practice guidelines and the overuse of health care services: need for reform , 2019, Canadian Medical Association Journal.

[9]  K. Bielefeldt,et al.  Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels , 2018, JAMA network open.

[10]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Detsky,et al.  Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study , 2017, British Medical Journal.

[12]  R. Moynihan,et al.  Mapping the drivers of overdiagnosis to potential solutions , 2017, British Medical Journal.

[13]  L. Bero,et al.  Industry sponsorship and research outcome. , 2017, The Cochrane database of systematic reviews.

[14]  D. Kreiner,et al.  Guideline summary review: an evidence-based clinical guideline for the diagnosis and treatment of adult isthmic spondylolisthesis. , 2016, The spine journal : official journal of the North American Spine Society.

[15]  Alison B. Evert,et al.  Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[16]  Grace A Lin,et al.  Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. , 2016, JAMA internal medicine.

[17]  Florence T. Bourgeois,et al.  Conflict of interest disclosure in biomedical research: a review of current practices, biases, and the role of public registries in improving transparency , 2016, Research Integrity and Peer Review.

[18]  Charles H. Cho,et al.  Guideline summary review: An evidence-based clinical guideline for the diagnosis and treatment of degenerative lumbar spondylolisthesis. , 2016, The spine journal : official journal of the North American Spine Society.

[19]  D. Rothman Professional Medical Associations and Divestiture from Industry: An Ethical Imperative for Pain Society Leadership. , 2016, Pain medicine.

[20]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[21]  L. Jovanovič,et al.  Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline , 2013, The Journal of clinical endocrinology and metabolism.

[22]  S. Hill,et al.  Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry: A Cross-sectional Study of Common Conditions in the United States , 2013, PLoS medicine.

[23]  D. Berwick,et al.  Eliminating waste in US health care. , 2012, JAMA.

[24]  Amy T. Wang,et al.  Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review , 2010, BMJ : British Medical Journal.

[25]  A. Evensen Management of COPD exacerbations. , 2010, American family physician.

[26]  Marilyn J. Field,et al.  Conflict of Interest in Medical Research, Education, and Practice , 2009 .

[27]  R. L. Addleton,et al.  Industry support and professional medical associations. , 2009, JAMA.

[28]  M. Talamini,et al.  Industry support and professional medical associations. , 2009, JAMA.

[29]  C. Deangelis,et al.  Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. , 2009, JAMA.

[30]  K. Garey,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  J. Lexchin,et al.  Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations. , 2017, The International journal of risk & safety in medicine.

[32]  Agnès Couffinhal,et al.  Tackling Wasteful Spending on Health , 2017 .

[33]  S. Temin,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.

[34]  Wu Guo-cheng,et al.  Prevention of COPD Exacerbations , 2012 .

[35]  Declaration of Interests for WHO experts. , 2002, International journal of occupational and environmental health.